Expanded NMN-based nutritional formulation
Expanded NMN-based nutritional formulation has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Oct 23, 2026: “Unlocking the Healthy Aging Potential of Novel NMN-Based Nutritional Formulations: Cardiopulmonary, Cognitive, and Aging-Related Outcomes in a 42-Day Open-Label Study”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1
“Exploratory biomarker analyses identified nominal between-group differences in CTACK (p = 0.015) and GDF-15 (p = 0.022), without adjustment for multiple testing”
None of its findings points the other way.
- 1 lab in 1 country
- Funder: Abe Yoando Pharma
- Human trial1
Studies in people
1 study gave expanded NMN-based nutritional formulation to people and measured what changed.
down: Decreases model-derived functional-age composite−2.79 years versus −0.63 years with placebo
Trial40 people45–65 years42 days
Midlife adults; Older adults; Exploratory placebo-versus-expanded-formulation subset
Nutrients, Oct 23, 2026
What did studies of Expanded NMN-based nutritional formulation find?
1Studies of Expanded NMN-based nutritional formulation measured 1 outcome; the most studied are model-derived functional-age composite (1 study).
Model-derived functional-age composite
downin humans1
1 study
Model-derived functional-age composite
downin humans1
Expanded NMN-based nutritional formulation decreases model-derived functional-age composite in humans (Exploratory placebo-versus-expanded-formulation subset) (−2.79 years versus −0.63 years with placebo).
“A model-derived functional-age composite decreased by 2.79 years in the expanded-formulation group compared with 0.63 years in placebo.”
Human trialExploratory placebo-versus-expanded-formulation subseteight-component formulation42 days
Nutrients
What is Expanded NMN-based nutritional formulation linked with?
1Studies link Expanded NMN-based nutritional formulation with 1 measure, most often CTACK and GDF-15 (1 study).
CTACK and GDF-15
mixedin humans1
1 study
CTACK and GDF-15
mixedin humans1
Expanded NMN-based nutritional formulation is associated with CTACK and GDF-15 in humans (Exploratory placebo-versus-expanded-formulation subset; no adjustment for multiple testing) (CTACK p = 0.015; GDF-15 p = 0.022; directions not reported).
“Exploratory biomarker analyses identified nominal between-group differences in CTACK (p = 0.015) and GDF-15 (p = 0.022), without adjustment for multiple testing”
Human trialExploratory placebo-versus-expanded-formulation subset; no adjustment for multiple testingeight-component formulation42 days
Nutrients